TARGETING SIGNAL-TRANSDUCTION FOR DISEASE THERAPY

With the advance in the molecular understanding of cancers and prolife rative disorders new approaches to managing these diseases may become feasible. It has been recognized that a key feature of these diseases is the pathological alteration in the molecular machineries of signall ing pathways. This recognition which began to emerge in the early 1980 s induced us to explore the possibility of targetting the aberrant sig nalling pathways for disease therapy. I now present evidence for the v alidity of the approach.